News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Helix Biopharma Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.
December 20, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Helix BioPharma Corp. (Helix; TSX, FSE: "HBP") today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Weight Loss
Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
March 25, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
March 25, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
March 25, 2026
·
3 min read
·
Tristan Manalac
Funding
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
March 25, 2026
·
2 min read
·
Tristan Manalac
